| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
|
Clarke, N.W.
|
|
|
30 |
12 |
p. 1992-2003
|
artikel
|
| 2 |
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
|
Corrie, P.G.
|
|
|
30 |
12 |
p. 2013-2014
|
artikel
|
| 3 |
Artificial intelligence for melanoma diagnosis: how can we deliver on the promise?
|
Mar, V.J.
|
|
|
30 |
12 |
p. e1-e3
|
artikel
|
| 4 |
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
|
Chaput, N.
|
|
|
30 |
12 |
p. 2012
|
artikel
|
| 5 |
Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors
|
Lange, M.
|
|
|
30 |
12 |
p. 1925-1940
|
artikel
|
| 6 |
Clinical relevance of TNM staging system according to breast cancer subtypes
|
Park, Y.H.
|
|
|
30 |
12 |
p. 2011
|
artikel
|
| 7 |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|
Morizane, C.
|
|
|
30 |
12 |
p. 1950-1958
|
artikel
|
| 8 |
Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation
|
Blay, J.-Y.
|
|
|
30 |
12 |
p. 2008-2009
|
artikel
|
| 9 |
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
|
Moro-Sibilot, D.
|
|
|
30 |
12 |
p. 1985-1991
|
artikel
|
| 10 |
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† † Approved by the ESMO Guidelines Committee: February 2002, last update September 2019.
|
Michielin, O.
|
|
|
30 |
12 |
p. 1884-1901
|
artikel
|
| 11 |
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
|
Ciavarella, S.
|
|
|
30 |
12 |
p. 2015
|
artikel
|
| 12 |
Editorial board
|
|
|
|
30 |
12 |
p. ii-iii
|
artikel
|
| 13 |
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
|
Dafni, U
|
|
|
30 |
12 |
p. 1902-1913
|
artikel
|
| 14 |
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
|
Pavel, M.E.
|
|
|
30 |
12 |
p. 2010
|
artikel
|
| 15 |
Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
|
Yoshioka, H.
|
|
|
30 |
12 |
p. 1978-1984
|
artikel
|
| 16 |
First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward
|
Kim, C.
|
|
|
30 |
12 |
p. 1852-1855
|
artikel
|
| 17 |
Gender medicine and oncology: report and consensus of an ESMO workshop
|
Wagner, A.D.
|
|
|
30 |
12 |
p. 1914-1924
|
artikel
|
| 18 |
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
|
Hammel, P.
|
|
|
30 |
12 |
p. 1959-1968
|
artikel
|
| 19 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
|
Marmorino, F.
|
|
|
30 |
12 |
p. 1969-1977
|
artikel
|
| 20 |
Lymphocyte infiltration predicts survival in chemotherapy-naive, triple-negative breast cancer and identifies patients with intrinsically good prognosis: have we been bringing owls to Athens?
|
Dubsky, P.
|
|
|
30 |
12 |
p. 1849-1850
|
artikel
|
| 21 |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
|
Gillessen, S.
|
|
|
30 |
12 |
p. e3
|
artikel
|
| 22 |
New realities of phase I clinical trials in the era of immuno-oncology: the durvalumab experience
|
Abdullah, S.E.
|
|
|
30 |
12 |
p. 2004-2007
|
artikel
|
| 23 |
Pattern recognition receptors: immune targets to enhance cancer immunotherapy
|
Shekarian, T.
|
|
|
30 |
12 |
p. 2017
|
artikel
|
| 24 |
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
|
Park, J H
|
|
|
30 |
12 |
p. 1941-1949
|
artikel
|
| 25 |
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
|
Yoon, H.H.
|
|
|
30 |
12 |
p. 2016
|
artikel
|
| 26 |
Systemic treatment of biliary tract cancer: now we have the evidence
|
Bridgewater, John
|
|
|
30 |
12 |
p. 1851-1852
|
artikel
|
| 27 |
Table of Contents
|
|
|
|
30 |
12 |
p. iv-vi
|
artikel
|
| 28 |
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † † Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version—Ann Oncol 2012; 23(Suppl 7): vii110–vii119.
|
Filetti, S.
|
|
|
30 |
12 |
p. 1856-1883
|
artikel
|
| 29 |
When is off-label off-road?
|
de Vries, E.G.E.
|
|
|
30 |
12 |
p. 2018
|
artikel
|
Tijdschrift beschrijving